This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
UnitedHealth (UNH) to Post Q2 Earnings: What to Expect?
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter results are likely to reflect improving premiums, products and higher expenses.
Can Centene (CNC) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Centene (CNC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's How Much a $1000 Investment in Centene Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Should iShares Morningstar MidCap Value ETF (IMCV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCV
Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCB
Centene (CNC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Centene (CNC) closed at $82.95 in the latest trading session, marking a -0.82% move from the prior day.
Centene (CNC) Stock Jumps 6%: Will It Continue to Soar?
by Zacks Equity Research
Centene (CNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Centene (CNC) Raises 2022 Guidance, Ups Share Buyback Fund
by Zacks Equity Research
Currently, Centene (CNC) has $3.6 billion remaining under its share buyback program.
Centene (CNC) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
Centene (CNC) closed the most recent trading day at $76.64, moving -1.06% from the previous trading session.
Centene (CNC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Centene (CNC) closed at $83.35 in the latest trading session, marking a +0.13% move from the prior day.
Zacks Industry Outlook Highlights UnitedHealth Group Anthem, Humana, Centene, and Select Medical
by Zacks Equity Research
UnitedHealth Group, Anthem, Humana, Centene, and Select Medical are part of Zacks Industry Outlook article.
5 HMO Stocks Set to Gain From Membership Growth, M&A Strategy
by Debasmita Chatterjee
Rising membership and a rapidly growing aging U.S. population are likely to drive the performances of the Zacks Medical-HMO industry players. UNH, ANTM, HUM, CNC and SEM are poised to benefit from improved operational efficiencies.
Centene (CNC) Stock Moves -0.28%: What You Should Know
by Zacks Equity Research
Centene (CNC) closed at $81.21 in the latest trading session, marking a -0.28% move from the prior day.
Why Is Humana (HUM) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Centene (CNC) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's How Much You'd Have If You Invested $1000 in Centene a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
UnitedHealth (UNH) Unit Chosen to Aid Missouri Medicaid Members
by Zacks Equity Research
UnitedHealth Group's (UNH) unit, UnitedHealthcare, has been selected by Missouri and entrusted to administer the MO HealthNet Managed Care Program to serve the state's Medicaid beneficiaries.
Select Medical (SEM) Shares Up on Q1 Earnings & Revenue Beat
by Zacks Equity Research
Select Medical's (SEM) first-quarter earnings benefit from higher patient visits and sound segmental contributions to revenues, partly offset by elevated labor expenses.
Cigna (CI) Q1 Earnings Beat on High Membership, Ups '22 EPS View
by Zacks Equity Research
Cigna's (CI) first-quarter results gain momentum from strong performances in Evernorth and Cigna Healthcare segments. A raised EPS outlook for 2022 remains noteworthy.
Ensign Group (ENSG) Down 5.1% Despite Q1 Earnings Beat
by Zacks Equity Research
Ensign Group's (ENSG) first-quarter results highlight sound contributions from the Skilled Services and Standard Bearer segments, partly offset by a rise in expenses mainly stemming from a higher cost of services.
Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
Community Health (CYH) Q1 Earnings Beat, Trims '22 EPS View
by Zacks Equity Research
Community Health's (CYH) first-quarter results benefit on the back of higher adjusted admissions and reduced interest expense. A lowered 2022 outlook for EPS might be a concern for investors.
Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCB
Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged
by Zacks Equity Research
Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.